CA2050298C - Dry powder inhalation device - Google Patents

Dry powder inhalation device Download PDF

Info

Publication number
CA2050298C
CA2050298C CA002050298A CA2050298A CA2050298C CA 2050298 C CA2050298 C CA 2050298C CA 002050298 A CA002050298 A CA 002050298A CA 2050298 A CA2050298 A CA 2050298A CA 2050298 C CA2050298 C CA 2050298C
Authority
CA
Canada
Prior art keywords
carrier
medicament
elongate carrier
chamber
elongate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002050298A
Other languages
French (fr)
Other versions
CA2050298A1 (en
Inventor
Peter D. Hodson
David K. Smith
Anthony C. L. Wass
David J. Velasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Priority to CA002354096A priority Critical patent/CA2354096A1/en
Publication of CA2050298A1 publication Critical patent/CA2050298A1/en
Application granted granted Critical
Publication of CA2050298C publication Critical patent/CA2050298C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0005Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0013Details of inhalators; Constructional features thereof with inhalation check valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0013Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • A61M15/0025Mouthpieces therefor with caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043Non-destructive separation of the package, e.g. peeling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0048Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0053Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
    • A61M15/0055Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0066Inhalators with dosage or measuring devices with means for varying the dose size
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0081Locking means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0091Inhalators mechanically breath-triggered
    • A61M15/0093Inhalators mechanically breath-triggered without arming or cocking, e.g. acting directly on the delivery valve
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007Mechanical counters
    • A61M15/0071Mechanical counters having a display or indicator
    • A61M15/0078Mechanical counters having a display or indicator on a strip
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0085Inhalators using ultrasonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0091Inhalators mechanically breath-triggered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/02Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A61M2016/0024Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with an on-off output signal, e.g. from a switch
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/82Internal energy supply devices
    • A61M2205/8206Internal energy supply devices battery-operated

Abstract

A dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet (s) to the patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.
The elongate carrier conveniently comprises a tape having a surface releasably bearing micronised medicament. The tape may be mounted in a removable cassette in a similar manner to a magnetic tape cassette.

Description

DRY POWDER INHALATION DEVICE
This invention relates to a dry powder inhalation device and in particular t:c an inhalation device capable of dispensing a pluralit~~~ of doses of medicament to a patient.
The invention alse> relates to an elongate carrier releasably supporting powdered medicament.
Asthma. and other respiratory diseases have long been treated by the :inha:Lation of appropriate medicament.
For many years the two most widely used and convenient choices of treatment have been the inhalation of medicament from a drug solution oz. suspension in a metered dose pressurised inhaler (MDI), or inhalation of powdered drug generally admixed with an exci.pient, from a dry powder inhaler (DPI). With growing concern being voiced over the strong link between depletion of t:he earth's ozone layer and chlorofluorocarbon (C'FC) emissions, the use of these materials in pressurised inhalers is being questioned and interest in DPI systems has been stimulated.
Existing single and multiple dose dry powder inhalers use either individual pre-measured doses or bulk powder reservoirs. In both cases only fairly large quantities (e. g. several hundred micrograms) can constitute a dose due to problE:ms associated with accurately transferring a measured small quantity of powder either into a capsule etc., or from a bulk reservoir within an inhaler. With potent drug: this introduces the necessity to add excipients, such as lactose powder, to increase the quantity of powder to be measured.. These excipients are ?0 undesirable, however, as t=hey pose subsequent powder deagglomeration problems and cause dryness in the patient's
2 mouth. In addition, the use of individual pre-measured doses tends to lead t.o the production of bulky inhalation devices.
Dry powder inhalers in which the medicament is introduced into the device from a capsule are disclosed in U.S. Patent Nos. 3,948,264, 3,971,377 and 4,147,166 and British Patent No. 1479283. Dry powder inhalers having a reservoir of dry powder from which unit doses are transferred to a chamber by means of a delivery system, such as a rotating perforated membrane in which the perforations arE_=. filled with powder from the reservoir, are disclosed in British Patent Application Nos. 2102295 and 2144997 and European. PatE:nt Application Nos. 69715, 79478 and 166294.
U. S. Patent. N~~~~. 4, 735, 358, European Patent Application No. 23980'? and British :Patent Application Nos.
2108390, 2122903 and. 216E~957 disclose vaporisers in which active substances capable of modifying the local atmosphere e.g. insecticides, deodorants and aromatics are vaporised for dispersion to the atrnosphere. The active substance is carried or impregnated on a belt o:r tape consisting of a suitable base material, in such a :M ate that vaporisation can be conducted at ambient temperature or under administration of localised heating by a vaporising head.
The substance is maintained in an inactive condition until the belt passes over the vaporising head whereby thermal release is achieved. T:he belt rnay be moved to the vaporising head by hand or at a fixed speed by a motor driving feed means thz:ough a reduction gear and is taken up by a shaft or spindle. In one embodiment the belt is 2a contained in a cassette to provide a re-usable device, the cassette being engaged by drive means and having a suitable aperture for the be1_t to pass acro~~s the vaporising head.
None of the vaporisers disclosed are suitable for delivering a predetermined unit dose of powdered solid medicament to a patient.
It has now been found that predetermined doses of a dry powder may be st~orec~ in and dispersed from an inhaler by means of a preloaded e:Longate carrier, such as a tape or 1.0 cord.
3 Therefore according to the present invention there is provided a dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier directly bearing a powdered medicament without the use of adhesive or microcapsules, the device being constructed and arranged such that areas of predetermined size of the elongate carrier are sequentially exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlets) to the patient port through the chamber such that particles of the powdered medicament of respirable size (viz., less than 10 microns) from said exposed area of the elongate carrier are entrained within the air flow.
The invention provides a simple, effective dry powder inhaler which is capable of delivering multiple, uniform doses of a medicament to a patient. The device is simple to operate and does not require the patient to insert capsules of medicament or rely upon a separate reservoir of medicament in order to load the device for use. The medicament is generally preloaded on an elongate carrier, sections of which are sequentially exposed in the chamber for dispensing the medicament. The elongate carrier may be conveniently loaded on a spool (in a similar manner to a photographic film) or in a cassette (in a similar manner to an audio cassette). The elongate carrier may have any ratio of length: width but is generally greater than 5:
1, usually greater than 10: 1 preferably between 100: 1 and 3a 1000: 1.
The preloaded elongate carrier can take a variety of forms, but preferably is a tape, web, belt or cord. The powdered medicament may be retained on the carrier by electrostatic attraction, van der Walls forces, physical attraction, mechanical binding, wedging or by a cover layer ..r ~n ~,TOr~ ~T; "n ~ a~TPr of the same carrier when. the
4 carrier is wound etc. One or more ~~urfaces of the carrier and optionally the interior of the carrier may be configured to assist in retaining the particles of powder.
The carrier_ may be constructed from one or more of a wide range of natural and synthetic materials e.g.
polyethylene, polypropylEme, polyester, polytetrafluoro-ethylene or a co-polymer thereof. and cellulose. The materials may be in t:he form of non-woven fibrous materials, loose weave materials or fabrics, materials having a surface pile, f:films, microporous materials, microgrooved materials, cords of twisted fibres, or any material or composit~> of more than one material having small surface grooves, recesses, int:erst~ices, apertures or embossed surface st:r_uctl:.res having a typical size of <500 ~,m in either depth or height and of greater than 0.1 ~m in at least one other dimension in order to retain the particles of powder.
A microgrooved material preferably comprises a tape, web or belt with one or more grooves of width 10 to 500 ~m at the carrier surf=ace and a depth of 10 to 500 ~.m, but the grooves may generall~r have dimensions at least an order of magnitude 1_arger than the largest particle. The microgrooves may be f:i_lled partially, or completely, the latter facilitating a means of dosage control if the material is loaded under' uniform conditions. The microgrooves need not: be continuous or straight and may run in one or two dimensions.
A microporous material preferably comprises a tape, web or belt having pores of diameter 0.1 to 100 um which may be randomly orientated. At least a portion of the pores must be on the exterior surface. A preferred method of pore formation util-~ses solvent extraction of oil droplets dispersed in a film or carrier material.
A further embodiment of a microporous material is produced by a laser drilling process and comprises a tape, web or belt having pores of diameter 1 to 100 Vim, preferably 20 to 50 ~,rr~, ir. at least one surface.
A non-woven material may be of any suitable format, but is preferably in the form of a tape, web or belt. It may contain any type and form of fibres, although fibres of 0.1 ~,m to 100 ~m diameter are preferred and most preferably 5 to 20 E~,m diameter. Fibres may be of any appropriate length but preferably 1 to 100 mm. Formation of the non-woven material rr~ay be any suitable method, for example, combing or cards.ng, deposition of fibres from a transport gas or fluid, o:r the extrusion and blowing of microfibres. Bonding, e.g. by thermal fusion, of the fibres over at least part of the area of the material may be carried out to increase the mechanical strength of the material. Such bonding may be most conveniently situated at the edges of the tape or web and many be conveniently formed as part of a process of slitting the tape, e.g., by a thermal or laser slitting means. The material may also be perforated or embossed and rnay optionally be air permeable.
The non-woven material may use a mixture of fibre compositions or forms. In one preferred embodiment, bicomponent fibres, with a readily-fusible outer component, are used. Such fibres are capable of ready inter-bonding to prevent, or minimise fibre shedding. In another preferred embodiment, spun-bonded fibres are u:~ed too achieve the same 3~ objective by taking advantage of their longer fibre length.
In a third embodiment, continuous reinforcing filaments may lie in the plane o:E the materia:L, so providing fibre anchorage and conferring additional mechanical strength to the material. In a fourth embodimeni~, paper type non-woven materials formed by deposition of fibres from a liquid may be used, as they may possess additional strength compared to other materials and may lead to reduced fibre shedding, due to increased fibre entanglement.
The tape, web o:r belt may contain reinforcing threads in the plane of the material and/or a backing layer e.g. a metal foil such as aluminium, or a polymer film or a combination thereof. A metallized backing layer is advantageous when the carrier is stored as a roll because it imparts a conducting surface, which may reduce transfer of medicament from t=he coated surface to the uncoated surfaces . The backing layer may have perforations to allow for passage of an airflow through the carrier material proper.
The carrier may be loaded by the brushing, scraping of smearing of powdered medicament onto the carrier surface.
Alternatively the carrier may be loaded by evaporation from a. ;suspension of medicament, by precipitation from a :solution of medicament or by deposition from an aerosol for example by spraying, impaction, impingement, aiffusion or by electrostatic or van der Waals attractions. For e~:ample, the medicament particles may be given an intentional electrical charge immediately prior to lo~iding. The technique of charged aerosol deposition ma.y b~ complime:nted by the use of a carrier with an inherent E:lectrostat:ic charge. Ideally, the 6 <~
carrier should be an insulator such as polytetrafluoroethylerLe capable of retaining the charge, alternatively the carrier may contain an artificial charge due to the presence of elect_rets. GE=_nerally, the choice of loading technique wil:1 be governed by the properties of the carrier material employed.
Masks stencils et:c. may be employed during coating, in order to allow the coating of discrete areas of carrier medium with individual doses. Patterned deposition of the medicament may be used to prevent contact between drug and any ink markings on t=ape .

A preferred carrier for use in this invention includes a flexible sheet material comprising a plurality of discrete depressions in at least one surface thereof, each of the depressions having a depth of about 5 to 500 ~.m, but less than the thickness of the sheet material, and an opening at the surface of the sheet material of about to 500 ~m across, a substantial number of the depressions being at least partially filled, preferably at least 75% filled, with micronised medicament, and the area 10 of the surface of the sheet material between the depressions being substantially free of micronised medicament.
The flexible sheet material may comprise a substantially regular array of depressions or microdimples formed in the top surface of a layer of polymeric material. The depressions are generally truncated cones, but may alternatively be of any suitable configuration for holding micronised medicament including generally truncated pyramids, partial hemispheres and tetrahedrons and other geometric configurations, as well as non-geometrical configurations. Presently preferred depres-sions have a sidewall angle of about 15 to 20° to the vertical. The array of depressions may take any form or pattern and need not be regular (i.e., the array may be irregular in appearance).
The depressions generally have a depth of about
5 to 500 ~,m and an opening at the surface of the sheet material of about 10 to 500 ~,m across with respect to the major axis of the opening. In the case of the depressions having generally circular openings such as truncated cones or partial hemispheres, for example, the major axis 7a discussed above is, in fact, the diameter of the circular opening. Preferred depressions have a depth of about 5 to 150 ~m and an opening (e.g., diameter in the case of truncated cones or partial hemispheres or the like) at the surface of the sheet material of about 50 to 200 Vim.
The depressions generally will be :paced about 20 to 200 ~.m, preferably about 5C to 200 ym, from one another.
Preferably the depre~,sions will number from about 500 tc 15,000 per cm2 of the sheet material. The volume of each depression and the spacing or number of the depressions will depend upon the potency of the medicament and the area of the sheet material int=ended to represent a single dose of the medicament. Preferably, the sheet material will have a substantially uniform depression volume per unit area.
The slueet material may further comprise a support layer, a . g . , of paper. The layer of polymeric material may be laminated or melt-bonded to or extruded onto the support layer. Other support layers may be Formed of non-wovens or polymers such as polyestez~.
The layer of polymeric material may comprise any suitable polymer such as polyethylene, polypropylene, polyester, polytetr<~f:luoroethylene and cellulose. Poly-ethylene is preferred. The layer of polymeric material will be typically about 25 to 7_000 ~,m in thickness.
The sheet rnateri.al may be formed of a single material such as polypropylene. The support layer is not required in such arn. embodiment since the sheet material even without the support layer wall exhibit sufficient integrity and durability.
A preferred. sheet material is prepared using polyethylene-coated kraft paper available from Schoeller Company. The depressions have a depth such that they do not form pores extending thr~~ugh the entire thickness of the ..0 sheet material.

The top surface of the sheet material is generally coated with micronised drugs to at least partially fill the depressions followed by general removal of excess drug from t-he top surface of the sheet material in the areas of the top surface bE=_tween the depressions, e.g., by scraping optionally followed by rolling between silicone pads, silicone having an affinity for the particles of drug.
As the packing density of the micronised medicament in the depressions may have influence on the form and amount of medicament released from the sheet material during the aerosolisation process, care should be taken to assure that the packing density remains substantially uniform during the coai~ing process.
The opening and depth dimensions and the spacing of the depressions influence how much micronised medicament the sheet material can carry per unit area for a given degree of compression of the medicament during loading or coating. Further, depression depth may influence the degree to which medicament is released from the sheet material and its relative state c>f agglomeration or unagglomeration.
Using albuterol sulfate with ,a mean particle size of 1.7 ~m and for single impaction~~ of strength appropriate to an inhaler on areas of about: 2 to 10 cm2 of sheet material, the following was observed. The percentage of medicament retained on the sheet material or tape decreases as depression depth increase~~, this being about 95% at 14 Vim, about 60% at 28 ~m and about 35% at 45 Vim. Further, the respirable fraction (i..e. , the percentage of drug which is in particles of aerodynamic diameter of equal to or less than about 6.4 Vim) similarly decreases as depression depth increases, this being about 65% at 14 ~,m, about 30% at 28 ~.m and about 10% at ~.7 Vim. These two trends result in the proportion of total medicament released in particles of respirable size remaining generally similar for the depression depths studied (this being about 5 to 15% of total medicament).
Depression~~ may be formed in the sheet material by any suitable technique such as micro-imprinting using a photolithograph.ically-patterned magnesium alloy plate 10 orother micro-machiner_~ plate. Other conventional techniques which may be used are optical imaging or laser imaging.
As an illustrative example a sheet material has been prepared using a phot;olithographically produced etched magnesium alloy master pl,~t=a having an array of pyramidal-shaped protuberances numbering about 1550 per cm2 wound about a steel roller. The roller wa:> heated to about 225°F
using oil. The polyethylene ~~urface of polyethylene-coated kraft paper (commercia.lly available from Schoeller Company) was pressed against the surface with. a rubber or steel nip roll, also heated w:it;h oi:i and hydraulically pressurised against the patterned roll.
It is preferred that the medicament employed exhibit a potency which permits a single dose to be loaded onto the sheet material in an area of less than about 25 cm2 and preferably less than about 5 cm2. More preferred is a sheet material containing a drug in such a manner and of such a type that between 0.25 and 2.:?5 cm2, most preferably between 0.5 and 2.0 c.m2, of the sheet. material will contain a single dose. Stated differently, given that a sheet material of the invention may conveniently carry between about 10 and 150 ~g o:E medicament per cm2, the potency of the medicament will preferably be such that a single dose may be carried on the above stated 0.25 to 2.25 cm2 of sheet material.
The format of the carrier in the most preferred embodiment is a tape. The nature of the carrier dictates the method of transport between storage means and the chamber where aerosol_isat;ion takes place. In a preferred embodiment, storage of preloaded carrier is effected by winding on a spool which is contained within a cassette.
Use of a tape web or' belt allows other conformations to be imparted to the stored carrier by folding, for example, as a concertina conformai~ion which has the advantage that the medicament bearing surface=s are in association and thereby prevent net transfer of medicament during storage. Each fold may define a unit dose of medicament. Folding along the longitudinal axis of t:he tape, referred to as hybrid folding, may also reduce unwanted net transfer of medicament. Cord or string may conveniently stored as a coil.
The device includes means for advancing the elongate carrier through the chamber to sequentially expose areas of the carrier for release of medicament during inhalation by the patient. The means for advancement may take a variety of forms depending upon t:he type of elongate carrier and whether t:he e:~posed areas of: carrier are to be retained within the device. For example, tapes webs and belts may include a series of apertures which are engaged by one or more sprc>cketed guide wheels or rollers in a similar manner to a r.amera or printer. Alternatively, or in addition, the carrier may be wound on a take-up spool, rotation of the spool directly or via a drive belt causing the carrier to advance. ~Che device may also include means for tensioning or otherwi:~e rrcaintaining the exposed area of the carrier within the c:harrcber during inhalation by the patient.
The elongate carrier may be advanced into the chamber prior to inhalation by the patient preferably or the carrier may be advanced into the aerosolisation chamber during inhalation tc_> prot;ect the powdered medicament from premature exposure. F'or c=_xample in one embodiment of the inhaler an unexposed are<~ of carrier is rapidly advanced into the chamber upon actuation, and is rapidly decelerated or brought to an abrupt halt and preferably is impacted thereby imparting sufficient energy to the medicament particles to effect their displacement: from the carrier into the air stx-eam.
In the preferred embodiment of the invention the elongate carrier is ~~torE;d in a cassette both before and after exposure. The :Jasset:te may comprise one or preferably two spools together with .idlers or other rollers and c0 include an exposure frame positioned within the chamber, through which the carrier .is advanced. 'rhe cassette may be removable to allow the dE~vice to be recharged with a new cassette. However, it i:~ not essential for the exposed areas of the carrier to be retained. within the device and spent carrier may be advanced to the exterior of the device through a slot in the housing whereupon disposal may be effected by the pat~.ient, optionally with the aid of a cutting edge. This arrangE:ment is particularly suitable for a tape carrier which has transverse perforations to 30 facilitate tearing off spent carrier.

The device preferably additionally comprises means for releasing medicament of respirable size from the exposed area of carrier independent of the patients' inspiratory effort. The medicament release means overcomes the binding of the medic<~ment particles to the carrier by mechanical effort e.g. impaction, vibrations, gas flow etc.
or electrostatically. Mechanical energy input may be achieved by:
impaction mean~~ e.g. one more spring biased 1.0 striking hammers having one or more impactions upon the exposed section of carriez,;
brushing or scraping means having rotary or reciprocal motion upon the exposed section of carrier e.g.
spring charged or electrically driven rotary elements having projecting bristles or flaps; dragging the carrier across irregularitie;~ such as a serrated idler wheel or a surface bearing a plurality of embossed structures or similar surface features;
pressurized gas flowing past, through or 20 impinging upon the carrier, emanating from some compressed or liquefied gas supply;
vibration means for imparting vibration to the exposed section of carrier, generally in the frequency range 5 to 50,000 Hertz; the vibrations may be derived electrically or p:iezo~~lectrically e.g. using the piezoelectrical proper.tie~ of polymer PVDF2;
electromagnetical:Ly e.g. use of an electro-magnetic vibrating arm or pin; or mechanically a . g. use of rotating cams or serrated wheels, which may involve rapid 30 revolution of the cam or wheel in contact with the carrier or movement of the carrier across the cam or wheel.

In a further emf>odiment vibration means may comprise means for the rapid acceleration of the elongate carrier, preferably from an unexpo~~ed storage state, into the chamber followed by a sudden and rapid deceleration preferably to a dead stop too facilitate medicament release.
In such an arrangement the particles of medicament are given sufficient kinetic energy such that they are released from the carrier when the carrier comes to a rapid halt. In a further embodiment the elongate carrier is maintained as 7.0 a s_Lackened loop following advancement into the chamber.
Upon actuation tensioning means effect a sudden and rapid straightening of the carrier loop causing particles of medicament to be displacE:d. The loop may be positioned in any orientation relative tc the patient port but in a preferred embodiment the centre of curvature of the loop is positioned between the ca==rier and patient port so that the particles of medicarnent are released towards the patient port when the loop is rapidly straightened.
Medicament release efficiency may be increased 20 when the carrier andfor the medicament particles have an intentional charge by reversing the polarity of the carrier at aerosolisation and inhalation.
The means for releasing medicament from the carrier during inhalatloTl 1S preferably triggered in response to the patient inhaling in order to avoid the patient having to synchronise inhalation and actuation of the release mechanism. Airflow detection may conveniently be accomplished by mean~~ of a movable vane positioned within the chamber or patient porn, motion of the vane 30 causing actuation of the release mechanism. Such a vane may also be constructed to prevent a patient exhaling through the device and/or preventing exhaled air from reaching the stored carrier thereby ,voiding any problems associated with moisture. Other such sealing means may also be employed. A suitable desiccant cartridge may be incorporated into the inhaler or may be incorporated into the carrier cassette.
Suitable medicament=s for use in the invention include any drug or dru~~s which may be administered by inhalation which is <~ solid or may be incorporated in a 10 solid carrier. Suitable drugs include those for the treatment of respiratory disorders e.g. bronchodilators, corticosteroids and drugs for the prophylaxis of asthma.
Other drugs such as anorectics, anti-depressants, anti-hypertensive agents, anti-neoplastic agents, anti-cholinergic agents, dopaminergic agent:s, narcotic anal-gesics, beta-adrenergic blocking agents, prostoglandins, sympathomimetics, tranquillisers, steroids, proteins, peptides, vitamins and sex hormones rnay be employed.
Exemplary drugs include:
Salbutamol, Terbutaline, Rimiterol, Fenoterol, Pirbuterol, Reproterol, Adrenaline, Isoprenaline, Ociprenaline, I=pratr~opium, Beclomethasone, Betamethasone, Budesonide, Disodium Cr-omoglycate, Nedocromil Sodium, Ergotamine, Salmeterol, E~luticasone, Formoterol, Insulin, Atropine, Prednisolone, Benzphetamine, Chlorphentermine, Amitriptyline, Imipramine, Clonidine, Actinomycin C, Bromocriptine, Buprenorphine, Propranolol, Lacicortone, Hydrocortisone, Fluocino:Lone, Triamcinclone, Dinoprost, Xylometazoline, Diazepam, Lorazepam, Folic acid, Nicotinamide, Clenbuterol, Bitolterol, Ethinyloestradiol, Levonorgestrel and pharmaceutically acceptable salts thereof.
The powdered medicament may be finely micronised by repeated step wise m~llings or a closed loop milling system and preferably is :in the particle size range of 1 to ~.m. The medicament may compri~~e one or more drugs, having one or more particulate forms and may include one or more physiologically acceptable or inert excipients. The medicament particles may possess a coating comprising a 1.0 surfactant, such as a perfluorinated surfactant or other surfactants such as Span f35, oleic acid, lecithins.
The predetermined area of carrier to be exposed in the chamber may be from 0.1 to 20 cm2 and preferably from 1 to 5 cmZ e.g. 2 to 3 cm2. 7_'he medicament may coat one or more surfaces of i:he carrier and/or be entrapped within recesses or interstices in the carrier to allow a dose of 5 ~g to 1 mg to be entrained within the airflow produced at inhalation. Its is not essential that all of the drug be entrained within the airflow providing the amount a0 of drug released from the predetermined area is substantially reproducible when the device is used.
The device of tree invention may incorporate means to indicate one or more of a variety of parameters, such as, readiness for use, ~~ontents remaining, type of drug etc.
The indicator rnay just provide warning of the near-exhaustion of the medicament supply or may provide more detailed information, such as the sequential number of the dose or the number of doses left. The indicator may 0 provide information of the date of manufacture or date of expiry of the medicamer:.t, as additional examples. For treatment intended to be taken regularly at set times, the indicator may display the intended day, date and time of administration. The information displayed by the indicator may conveniently be marked on the tape or tape covering by any appropriate method, whether involving printing, indenting etc. The area of tape in the indicator need not be that used to x~elea~;e she drug at that time . The indicator may be of an extremely :gimp=Le form, such as a window or aperture to revf=_al the amount of elongate carrier 1.0 remaining on the supply spool of a cassette, the window being visible externally or when a cover is opened to expose the cassette within the device.
The device may incorporate means to vary the area of elongate carrier exposed in the chamber thereby providing a variable dose facil=ity. For example, an internal cover for the elongate carrier may be provided which is movable to expose varying lengths of carrier to the chamber. Alternatively, or additionally, rollers supporting the exposed length of the carrier may be movable ~0 to vary the distance between the rollers thereby altering the exposed length o:f the carrier.
The device: of t;he invention may possess numerous advantages over the prior art devices. For example:
1. An inhaler vrith dosage control by the removal of powder from a fixed area of uniformly coated tape may show improved dose uni:Eormity and respirable fraction uniformity over prior art devices. High respirable fractions are desirable because they allow a high proportion of the drug too be inhaled into the lungs to ?0 provide therapeutic benefit, and reduce the proportion of the drug causing unwanted s~,rstemic side-effects following swallowing from the mouth and throat region.
2. The inhaler allows th.e accurate administra-tion of smaller quantil~i.es of undiluted potent drugs (typically below 200 ~,g) such as corticosteroids, than is currently possible. 'This removes the problems associated with the use of excipi.ent:> .
3. The storage of pure, powdered medicament on the surface of a tape lends itself to dosage adjustment or the use of different. drugs with the minimum of effort and without reformulation work.
4. The inhaler is suitable for use with a wide variety of different medicaments.
5. By cont=rolling the tape or web dimensions, a precise number of doses for inhalation can be stored in the inhaler.
6. The tape can be marked to allow the inhaler to register the exact number of doses remaining, or alternatively some counter mechanism can be driven by the carrier advance mechanism.
7. If indirect breath act=uat:ion is incorporated the amount of drug inh~.led and the degree of particle deagglomeration are independent of the patient's inspiratory effort in the inhaler. Indirect breath-actuation can be used in this invention, offering the advantage for such devices of being able to overcome patients' hand/lung c:o-ordination problems, while at the same time prov:i_ding a consistent dose each time for all patients, irrespective of lung function.
8. Ii. indirect breath actuation is incorporated the deagglomera.tion c>f the drug is not dependant on air flow rate, so that patients can be taught to inhale slowly (unlike for most dry powder inhalers), thus reducing unwanted drug impact:LOn on the back of their throats.
The invention will now be described with reference to the accompanying drawings in which:
Figure la i~~ a section through an inhaler of the present invention having a single integral carrier storage spool, Figure lb is a section through a disposable cassette for an inha:Lex~ of the present invention comprising a single carrier storage spool, Figure 2 is a section through an inhaler of the present invention haring a carrier of cord stored as a coil and integral take-up spool, Figure 3 is a section through an inhaler of the present invention having a cassette comprising spooled carrier storage and take-up means and impaction means for aerosolisation, Figure 4 is a section through an inhaler of the present invention having concertina folded carrier storage and integra7_ take-up spool, Figure 5 is a section through a variant of the dry powder inhaler o~~ Figure 4 having hybrid folded storage in addition to concex:~tinaed stacking of carrier, Figures 6a to 6d illustrate an inhaler of the present invention having indirect breath actuation, prevention of through exhalation vane and impaction means for aerosol-sat ion. l:~ figure 6a is a front view, Figure 6b a rear view and Figure 6c a ventral view of the device 3~~ exterior. Figure 6d i;~ a transverse section through the inhaler along the axis A-A, Figures 7a to 7c illustrate an inhaler of the present invention having manual actuation of impaction means for aerosolisat:ion. Figure 7a is a front view and Figure 7b a. rear view of the device exterior. Figure 7c is a transverse section through the inhaler along the axis B-B, Figure 8a i;~ a section through an inhaler of the present invention having a revolving brush for aerosoli-sation of carrier borne medicament, 10 Figure 8b i:~ a transverse section of the inhaler in Figure 8a along t:he axis C-C, Figure 8c is a transverse section through a variation of the inha_Ler illustrated in Figure 8a having indirect breath actuation, Figure 9 is a section through an inhaler of the present invention r-laving a cassette comprising spooled carrier storage and tah:e-up means, a recessed wheel driving a gear train for dose advancement and an electromagnetic vibrator, 20 Figure 10 i~; a section through an inhaler of the present invention having a carrier comprising a sheaf of sheets, Figures lla to 11c illustrate an inhaler of the present invention, having indirect breath actuation of scraping means for medicament aerosolisation and a housing assembly having a c~:wer. Figure lla is a section through the device in closed format; Figure llb is a section through breath actuation means at patient inhalation and Figure llc is a secticn through the device in open format at medicament aerosolisation, Figures 12 and 12b illustrate sections through alternative inhalers c>f= the present invention, Figures 13 t:o 29 represent cross-sections through a further device in accordance with the invention, Figures 30 a:nd 3:1 represent cassettes containing elongate carrier in accordance with the invention, and, Figures 32 t:o 35 represent cross-sections through devices in accordance with the invention adapted to contain the cassettes of Figure 30 or Figure 31.
Referring to Figure la, an inhaler of fully disposable format is illustrated, comprising a housing (1) having integral ai.r vents (2) and defining an aerosolisat:ion chamber- (3) in communication with a patient port (4), having a mouthpiece adaptor (5) in this embodiment. Alternatively, the device may be fitted with a nasal adaptor (not shown) or the device may be supplied with both. Within said chamber are integral carrier storage spool (6) and carrier engaging rollers (48) which may be sprocketed to engage the carrier by means of a series of apertures cut in the carrier.
Carrier (8) is sequentially advanced across the exposure frame (9) and subsequent to exposure, through slot (49) in the housing. :3pent carrier may be discarded by the patient with the ai.d of cutting edge (50) in a process analogous to a cap gun or tape dispenser. Dose advancement means are not shown but may comprise mounting rollers (48) on a drive shaft extending through the housing (1). This may be manually turned with the aid of a knurled knob.
Alternatively a suit=able gear train may be connected to rollers) (48) and a recessed dose advancement lever or wheel mounted in the housing to effect dose advancement.

Figure lb i:~ a section through a cassette of preloaded carrier c~:muprising: a cassette housing (16), a carrier storage spool (17) and free carrier leader portion (18) which is inserted into a device take-up means. Such a cassette is suitable. f:or use in the inhaler of Figure la (optionally as a r.~e-usable device) where the cassette replaces spool (6). 'fhe leader portion upon loading would be threaded, in a m.a.nner analogous to loading a 35 mm photographic film l.~o engage rollers (48) and protrude through slot (49) . Alternatively the leader portion may be inserted into a take--up spool by means of a slot cut in said spool.
Referring tc> Figure 2, an innaler oz sully disposable format is illustrated, comprising a cord carrier (26) stored as a coil (27) in a storage compartment (28) distinct from aerosoli-Nation chamber (3). Means for sealing stored cord from moisture ingress may be provided at opening (52). Sequent=ial advancement of cord under tension by sprung .rollers (24) to exposure frame (9) allows for aerosolisat:ion of the medicament carried. Subsequent to exposure, spent carrier (29) is taken up by integral spool ( 7 ) . Dose advancement means are not shown but may comprise a shaft continuous with the spindle of spool (7) extending through the housing and turned by means of a knurled knob, or by a suitable dear train engaging spool (7) and connected t.o a recessed dose advancement wheel or lever mounted in the housing.
Referring to Figure 3, an inhaler of re-usable format is illustrated comprising a disposable cassette (10) having carrier storage spool (11) and take-up spool (12).
Spools (11,12) are engaged respectively on cassette insertion by spindle~~ (1.1a,12a). The embodiment depicted comprises i.mpaction means (13) for the aerosolisation of medicament at expo::;ure frame (9) upon release, either manually or indirectly by breath actuation means, explained hereinafter, of a spring biased hammer (14) held in an armed position (as il:Lustrated) by catch (15). Means for arming the :hammer are not shown.
An inhaler c~f fully disposable format is produced by replacing cassette (101 with integral spools (6) and (7) .
Referring too Figure 4, an inhaler having folding means of carrier ~=>torage is illustrated, comprising a carrier stc~rage compartment (22), wherein carrier (8) is stored in a concertinaed configuration (23) such that medicament bearing surfaces are in association. Carrier is sequentially advanced under tension by rollers (53) which may be spring b=iased or sprocketed to engage the carrier in register and providE:~ ~~upport means. Spent carrier exposed at exposure frame (9) is taken up by integral spool (7) which interacts with d.c>se advancement means.
Referring l.~o Figure 5, a variant of the inhaler depicted in Figure 4, comprising carrier (8) being folded across the longitud:in.al axis prior to concertina folding (23). Medicament bearing surfaces of the carrier are folded inwardly to prevent net medicament transfer and to reduce moisture ingress. Sequential advancement of carrier, by drive means associated with integral take-up spool (7) and under tension provided by roller (53), causes unfolding of carrier immediately prior to exposure at exposure frame
(9). Mouthpiece (5; is depicted with dotted lines to illustrate positioning.

Referring to Figure 6a, a front view of an inhaler having indirect. breath actuation of impaction means is illustrated. Vane (56), explained hereinafter is shown in the displaced posii~ion. Exposure frame (9) presented to the patient by insertion of mouthpiece (5) into the buccal cavity defines the e~:posed area of carrier (8). Striking hammer (14) is held in an armed position by catch (15) and is released by the detection of an air flow through the device.
Figure 6b depicts a rear view of the inhaler of Figure 6a and illustrates the position of air vents (2), striking hammer arming rod (54) and dose advancement lever (40) recessed in slot (55) .
Figure 6c depicts a ventral view of the inhaler of Figure 6a and serve:~~ to illustrate the housing extension (58) containing ind:irE:ct breath actuation means and the arming rod (54) in non-armed position flush with the housing.
Figure 6d depicts a section through the inhaler along the axis A-A. The inhaler comprises: a housing (1) having an extension (58), for purposes of indirect breath actuation with integral air vents (2), said housing defining an aerosoli~~ation chamber (3) in communication with patient port (4) and air vents (2). Carrier (8) is taken up by spool ( 7 ) . Carrier storage means are not shown but typically would be a spool.
Unexposed carrier (8) is sequentially advanced across exposure frame (9) by recessed lever (40) driving a suitable gear train (41) turning spool (7). Striking hammer (14) is primed by the patient immediately prior to inhalation by retracting spring biased rod (54) until catch (15) is engaged.
Vane (47) i;~ capable of being displaced when an air flow is generated by patient inhalation through the device . The vane is spring biased (not shown) to return to the displaceable home position when the air flow is halted.
Displacement of the v<~ne (47) produces an interaction with catch (15) to release the striking hammer (14). Impaction of the hammer with carrier (8) releases medicament
10 particles c>f respirable size into aerosolisation chamber (3), whereupon they are entrained into the developing air stream as the patients inspires.
Vane (56) en.~;ures unidirectional flow of air from the exterior atmosphere, vi.a air vents (2) to patient port (4), by being displaceable in the forward direction only.
Movement in the rever~~e direction upon patient exhalation is prevented by stop (~7).
In a modification (not shown) the vanes (47) and (56) may be replaced by a simple vane.
20 Referring to Figures 7a to 7c, an inhaler having a cord carrier and manually circulated impaction means for aerosolisat=ion. Cord (27) is sequentially advanced across exposure frame (9). Rod (54) is retracted immediately prior to use until the hammer (14) engages catch (15). The patient inserts the inhaler into his oral or nasal cavity and depresses button (44) which connects with spring biased lever (46) to cau~;e catch (15) to release the armed striking hammer. t:h~~ hammer contacts the cord with sufficient energy input to aerosolise medicament particles of respirable size. Simultaneously inspiration produces an air flow through the device entraining aerosolised medicament to the patient.
Referring to Figures 8a to 8c, an inhaler of fully disposable format having both integral spooled carrier storage (6) and take-up (7) and brushing/scraping means for aerosolisat:ion. Carrier (8) is sequentially advanced across the carrier_ support (42) in contact with a spring powered or electrically driven (not shown) rotary brush (43). Contact is only made between brush filaments and carrier at the exposure frame (9). Synchronisation of brush action with e:x~>osure of a fresh section of tape is achieved by the embodiment illustrated by Figures 8a and 8b in which a push butt:o:n (44 ) interacts with a spring biased check pawl (45) to prevent advancement of carrier by a recessed lever (40) and suitable gear train (41) until the button is depressed. The same push button or a different push button switch when depressed may complete a circuit comprising a battery <~nd a motor (not shown) or allow a tensioned spring mecranism (not shown) to revolve the brush. Alternatively t:he gear train (41) responsible for carrier advancement may interact with the brush directly, thereby synchronising their motion.
Figure 8c illustrates the application of indirect breath actuation to a further embodiment of the device whereby a vane (47) movably displaced by a developing air stream during patient inspiration, completes an electrical circuit containing a battery and a motor driving rotary brushing ( 4 3 ) .
Figure 9 illustrates an inhaler of re-usable format with part of- the housing and disposable cassette (10) cut away. The cut away illustrates the relative position of carrier storage spool (11) and carrier take-up spool (12) within sa=id cassette to the gear train (41).
Sequential advancement of fresh carrier (8) to exposure frame (9) is completed by a recessed dose advance wheel (38) engaging gear train (41) and revolving take-up spool (12). Electromagnetic vibrator (37) is activated by completion of a circuit: containing a battery cell. This may be achieved by a push button or the action of a displaceable vane (not shown) as described in Figures 8a to 8c. Vibrating head ~;E~O) contacting the carrier at the exposure frame causes the release of medicament into chamber (3) where it may be entrained by the patients inspiratory efforts.
Referring to Figure 10, a section through an inhaler of fully disposable format comprising sheets of carrier (30) stored as a sheaf (31) in a storage compartment (32). The sheaf is supported by a spring biased plate (33) such that. individual sheets can be advanced by means of rollers (~~4) which may be sprocketed engaging carrier sheets with suitable apertures in register to an exposure frame (9) ~:~rior to aerosolisation. Spent carrier sheets are ejected by rollers (34) through a slot (35) in the housing (1) for disposal by the user.
Figures lla. to llc illustrate sections through an inhaler (75) having a housing (76) comprising casing (78) and a cover ( 77 ) pivot:ally mounted at ( 79 ) movable between a closed format shown in Figure 11a and an open format shown in Figure llc. The inhaler is maintained in a closed position whilst not in use providing a compact, convenient shape minimising contamination from dirt, moisture ingress etc.

The housing has one or more integral air vents (2a), which are exposed when the device is in the open format, and defines an aerosolisation chamber (3) in communication with a patient port (4), having a mouthpiece adaptor (5). Vdithin the chamber are integral carrier storage spool (6), idler (81) having four lobed catches (86) of equal dimen~;ion, and carrier take-up spool (7) having a pawl (82) and ratchet (83) allowing unidirectional rotation of the spool (indicated by the arrow of Figure 11c) .
The device ins cocked for use by fully opening the cover (77) causing tensioning of the device spring (89) which acts on drive peg (84) which is engaged in a slot (90) in carrier take-up spool (7). Rotation of take-up spool (7) by the drive peg (84) is prevented by the engagement of displaceable idler catch (86) with vane pivot axle (85a). Opening the device exposes the patient port and mouthpiece adaptor to the patient.
Figure 111: illustrates the actuation of the device by a developing airstream as the patient inhales.
Vane (85) provides indirect: breath actuation means and may additionally prevent through device exhalation by the patient . The vane is pivoted so as to be displaceable when an airflow is generated through the device from the exterior via vent: (2a) to the patient port (4) .
Unidirectional displacement of vane (85) is provided by the vane engaging stop (57). The vane may have a width equal to the patient port :~uc~h that upon exhalation the vane sealingly contacts slop (57) preventing the ingress of moist, exhaled air. =Cn the home (non-displaced) position the vane engages catch (86) preventing carrier uptake.

Inhalation displaces vane (85) into recess (91) whilst displacing and freeing idler catch (86) from engagement by vane pivot axle (85a) and allowing idler (81) to complete the cycle until the following catch (86a) re-engages the vane pivot axle. The curvature of each catch aids the stepwise engagement of vane pivot axle (85a) to define dosage lengths of carrier.
Referring to Figure llc, medicament is removed from the carrier by a combination of the patient's inspiratory effort, acceleration/deceleration impaction and the act ion of scrapes= ( 8 7 ) . With idler ( 81 ) free f rom interruption the tensioned spool (7) rapidly winds up carrier ( 8 ) under the =_nf luence of drive spring ( 8 9 ) moving drive peg (84) until l~he passage of idler (81) is abruptly halted by the next catch (86a) re-engaging pivot axle (85a). The resulting momentum of medicament particles, the impaction due to the arresting of carrier velocity and the resulting vibration of= the carrier aid medicament removal.
The curvature of idle=r (81) bends the carrier with drug coating outwards as each new unexposed section is indexed onto the idler (81) and exposed to the airstream, thereby easing the release of powder. Scraper (87) aids the release of medicament by contacting the exposed area of carrier prior to take-up and mechanically displaces the medicament particles. After use the device is returned to the close format by the patient, the drive peg (84) being returned to its original position under the influence of return spring (80) .
Figure 12a and 12b illustrate alternative embodiments of a variation of the inhaler illustrated in Figures 11a to llc. Both devices are shown in the inactive closed format.
Figure 12a illustrates an inhaler (93) having a spring biased cam follower comprising a spring (95), biasing wheel mounting (96) and bearing cam follower wheel (97). Cam follower wheel (97) engages and travels the surface of cam (98) during cam rotation. Cam (98) has an essentially square cross section and abuts idler (99) having four displaceab7_e catches (100) of equal dimensions.
10 Vane (85) provides indirect breath actuation means and may form a one way valve preventing exhalation through the inhaler. The device is cocked as described previously for Figures lla to 11c, movement of the carrier being prevented by engagement of catch. (100) with name pivot axle (85a) .
When the patient inhales, vane (85) is displaced into recess (91). Idler (99) is no longer blocked allowing carrier (8) to be drawn onto take-up spool (7). As the carrier is taken up, passage of cam follower wheel on the surface of cam (98) for the first 45° of rotation 20 compresses spring (9.5) such that during the second part of the cycle (a further 45° rotation), cam follower wheel (97) causes the cam to rcita.te faster than take-up spool (7) . A
loop of carrier (not. shown) develops until idler (99) rotation is prevented by engagement of following catch (100a) with vane pivot axle (85a). Subsequently the loop of carrier is snapped t=fight by take--up spool (7) causing release of medicament:: into the airstream.
Figure 12b i7_lustrates an inhaler (105) having a cam assembly comprising a central cam (107) of essentially 30 square cross section abutting a guide wheel (108) bearing carrier (8) and an interrupter wheel (109) having, at the four compass positions, circular elements (110) of equal dimensions and .freely ~=otatable about axis; a spring biased cam follower comprising a spring (95) biasing wheel mounting (96), suppc.~rt.ing cam follower wheel (97) and an interrupter assembly comprising a rocker arm (112) pivoting about pivot: point (112a) and bearing a peg (114) and a catch (115) having a ~~pring leaf (116). Catch (115) is able to pivot about pivot:. point (113). Cam follower wheel (97) engages and travels the surface of central cam (107) during rotation of the cam a:>~~embly. Rocker arm (112) is biased by the act ion of a weak. spring ( 117 ) , f fixed between peg ( 118 ) of housing (1) and slot (119), such that the rocker arm nose (112b) stepwise engages circular elements (110) at every 90° rotation oa- the cam assembly.
The device depicted illustrates alternative embodiments to the format of the drive (89) and return (80) springs described previously and the idler/ratchet mechanism ensuring unic~irectiona:l rotation of carrier take-up spool (7).
In use, tine device is cocked as described for Figures lla, 11c and 12a by opening of the cover, whereby drive peg (84) is ten~,i.oned by the activity of drive spring (89a). Unidirectiona:L !clockwise) rotation of take-up spool (7) is effected by t:he action of spindle (121) having a series of ;stepped projections (121a) engaging the spring leaves (122) of the spool in the reverse (anti-clockwise) direction. Tensionec:~ drive peg (84) imparts a slight rotation to take-up :pool (7) causing tightening of any slack carrier (8). Rot=ation of the take-up spool (7) is prevented by the engagement of rocker arm (112) to the interrupter wheel (:109), but the rocker nose (112b) is caused to be displaced slightly on the circular element (110a) . The slight 1-ift imparted to the rocker nose (112b) in a reciproca=L motion about- the pivot causes catch ( 115 ) to engage the curved surface (123). The curved surface (123) directs catch (115) too rest upon vane (85) . Vane (85) provides indirect breath actuation.
Patient inhalation through mouthpiece adaptor (5) displaces vane (85) into recess (91) as described previously. Rogation of the vane about pivot point (124) 7.0 causes the displacement of catch (115). As catch (115) is displaced from a blocking to a non--blocking position, rocker arm (112) is lifted by interrupter element (110a) thus allowing rotation of cam assembly. Rocker arm (112) is maintained in contaci~ with surface of interrupter wheel (109) by spring (11.7) so that it contacts the following interrupter element (110b). This provides a stepwise mechanism (evez-y 90° rot:ation of the cam assembly) for carrier exposure. Co--operation of central cam (107) and spring biased c:am follower cause a loop of carrier to be 20 formed which is snapped t=_ght causing release of medicament particles as described in Figure 12a.
Figures 13 and 14 represent a cross-section through a further inh<~lat ion device in accordance with the invention showing the device with the cover closed for storage and with the cover open in the dispensing position respectively.
The device comprises a housing (200) defining a chamber (202) in communication with a mouthpiece (204). A
cover (206) is pivotable about pivot. point (208) between a 30 closed position as showed in Figure 13 in which the contents of the device are protected against ingress of moisture and contaminates, and a dispensing position, ready for patient's use, as shown in Figure 14.
The housing (200) contains an elongate carrier bearing powdered medicament which is held within a removable cassette shown in dotted outline at (210). The cassette comprises a supply spool (212) which initially holds the bulk of the elongate carrier wound in the form of a roll. From the supply spool the elongate carrier passes round an idler roller (21.4) and a spiked control roller _~0 (216) to a take-up ~~poo7_ (2.18) . An area of the elongate carrier between the idler roller (214) and the spiked control roller (216) is exposed to the chamber (202); when the device is actuated powdered medicament from this exposed area is released from the elongate carrier and entrained in the pat:ient':~ airflow through the chamber.
The device is very simple to operate requiring only that the patient opens the cover (202) and inhales through the mouthpl.ece (204). This action activates a fairly complex sequence of operation of four separate 20 mechanisms. These mechanisms comprise a driving mechanism for advancing the elongate carrier, driven by a spring which is cocked by opening the cover; a trigger mechanism which ensures the energy stored in cocked drive spring is not released until inhalation is sensed, an impaction mechanism which cau~>es t:he exposed area of the elongate carrier to be impacted ensuring release of medicament into the air stream and a braking mechanism which holds the elongate carrier taut whi=Le the impaction takes place. For ease of comprehension the components and action of the 30 individual mechanisms will be described separately.

Figures 15 to 17 illustrate the drive mechanism for advancement of the elongate carrier. The drive mechanism comprises a drive :spring (220) positioned between the drive gear (222) anc~ the portion (224) of the cover (206) ; when the coven (206) is clo:~ed over the mouthpiece it is lightly held shut by the action of the drive spring.
Figures 15a, :LSb, and 15c, represent cross-sections at different heights through the drive arrangement generally shown within the circle (I) for the take-up spool 7.0 (218) of the cassette (27_0) (shown in Figures 13 and 14) .
The drive from the=_ take-up spool pinion (226) is transmitted via a sprin~~ (228) and ratchet arrangement comprising a ratchet gear (230) and ratchet pawl (232) to a spool-driving peg (234) which engages with the take-up spool of the cassette. T:he :spring (228) allows the drive gear to move the pinion through a greater angle of rotation than the elongate carrier allows the spool to move. The ratchet arrangement allow: the drive gear to be reset without unwinding the tape from the t=ake--up spool.
20 Figures 15d and 15e represent cross-sections at different heights within the circle (II) and illustrate how the drive from the control roller pinion (236) is transmitted via a ratchet; mechanism comprising a ratchet gear (238) and a pawl (240) mounted on the control roller pinion so that the mechanism may be reset without moving the control roller anc~ elongate carrier. The casing of the ratchet gear (238) is in the form of an escape wheel having stops (242) which interact with the triggering mechanism to limit the movement to one re~aolution per cycle. The drive 3~ from the control rot-ler pinion is finally transmitted to the control roller via a drive spigot (244).

Figure 16 shows the cover (206) opened to expose the mouthpiece and to cock the drive or advancement mechanism by applying pressure to the drive spring (220) caused by movement of the pc>rtion (224) of the cover when the cover is pivoted about its pivot point. Although the drive spring (220) is loaded the drive gear and associated pinions cannot move as tree control idler is locked by the escapement (242 ) (Figures 15d and 15c~) .
When the escapement. releases the control idler, 10 movement of the drive gear (222) and associated pinions (226 and 236) is effected under the influence of the drive spring (220), the direction of movement of the components being shown by the arrows o:n Figure 7_7.
After actuation of the device, when the cover is closed as shown in Figure 18, a step (244) on the cover (206) engages a spigot (246) on the drive gear (222) returning the drive mechanism to its initial position and causing rotation of the pinions (226 and 236) as shown by the arrows in Figure 18.
2~ The components and mode of action of the breath actuated triggering mechanism is depicted in Figures 19 to 23.
In addition to the escape wheel comprising stops (242) on the control idlez- shaft, th.e tz-iggering mechanism comprises a pivoting vane (248) which is capable of pivotal movement about pivot point= (250), and an escapement lever (252) which is pivoted about pivot point (254). When the vane is closed and abuts :stop (256) the step (258) on the escapement lever abuts St~Up (242) on the escape wheel.
30 Pivotable movement of the escapement lever (252) is prevented by engagement of a projection (260) on the 35a escapement lever with a curved abutment surface (262) formed near the pivot point (250) of the vane. When the cover is opened as shown in Figure 20, the drive spring (220) is tensioned but movement of the drive gear (222) and the control roller (236) in the direction of the arrows is prevented by the escapement wheel. When the patient breathes through the mouthpiece the vane (248) is lifted by the airflow as shown in E~iaure 21.. Movement of the vane (248) allows pivotal rnovernent of the escapement lever (252) 1.0 moving the step (258) on the escapement lever away from the stop (242) on the escapement wheel thereby allowing rotation of the control roller pinion (236), the gear train (222) and the take-up spool pinion (22E~). Rotation of the pinions (226 and 23E>) causes rotation of their associated spigots (234 and 244) thereby rotating the take-up spool (218) and control roller (216) of the cassette (210).
When the control roller (216) has completed almost one revolution, a second stop (242) on the escape wheel contacts step (262) of the escapement lever (252) 20 (Figure 22) and the control roller and hence the elongate carrier are arrested.
After the device has been used and the cover (206) is closed the vane ~~ivots back to its closed position and the escapement lever (252) is pushed up to release the engagement between the step (262) and the escapement wheel and step (258) on the escapement lever (252) engages the stop (242). The movement of the various components is depicted in Figure 23 :by the arrows.
The device comprises means to facilitate release 3~ of the powdered medicament :From the elongate carrier in the form of an impaction mechanism which is depicted in Figures 35b 24 to 26. After the patient has bcygun to breathe through the mouthpiece relea~;i.ng the triggering mechanism, and the elongate carrier has been advanced by the drive mechanism, the area of the carrier expo:~ed to t=he chamber is struck by an impactor arm driven by a powerful spring to release medicament from the e:Long,~t:e carrier into the air stream.
Figure 24 shows t=he impact.or mechanism comprising an impactor arm (264) which is pivotally mounted about pivot point (266) and hay: an impaction head (268) which ._0 strikes the elongate carrier (not shown). The impactor arm is biased by spring (2.70; . The impactor- arm is held clear of the elongate carrier by a catch (272) which engages the impaction head (268) until the triggering mechanism is activated. 6Vhen the triggering mech<~.nism has activated the drive mechanism and i~he escapement wheel rotates, one of the stops (242) acts as a cam to push the catch (272) against its integral :spring (274) and releases the impaction head thereby allowing pivotal movement of the impaction arm under t:he influence of the spring (270) so 20 that the impaction head strikes the exposed area of the elongate carrier (not shown). The direction of movement of the catch (272) and the irnpaction head (268) is shown by the arrows in Figure 25.
Figure 26 shows the impaction device being reset during closing Of thE' cover (206) . Cam surface (276) is provided on the cove..r which bears against the impactor arm turning it to its origina:L position and compressing spring (270). During this movement the impaction head slides up catch (272) ini_tiall.y moving the catch back against its 30 integral spring (274) until the impaction head is clear of the stop (278) of the catch and thereafter the catch moves 35c to its blocking position engaging the i.mpaction head under the influence of its :rote<~Y-al spring (274) .
In order t.o ensure efficient release of powdered medicament from the elongate carrier it is necessary that the exposed area of the elongate carrier is held taut while being struck by the impactor head. The control roller and take-up spool prevent the elongate carrier from retreating by virtue of the :ratchet arrangements described with reference to Figures 15b and 15d. In order to prevent the carrier spool from unwinding during impaction, the carrier spool is arrested ju:~t prior to impact:ion by means of a pawl which engages a ratchet: wheel (282) attached to the carrier spool shaft. Normally, the pawl (280) is held out of engagement with the r;at:chet (282) by contact with the impaction head (268) of the impactor arm (264) (Figure 27), but once the impactor arm moves towards the elongate carrier, the pawl (280) springs inl:o engagement with the ratchet (282) under the influence of spring (284) (Figure 28). This engagement pr~=vents further' rotation of the carrier spool thereby arresting the advancement of the elongate carrier, securely holding the length of the elongate carrier between the carrier spool and control roller so that t:he irnpaction head strikes the taut elongate carrier thereby impartin<~ sufficient energy thereto to cause powdered medicament to be released into the air flow caused by the patient's inspiration through the mouthpiece.
During closing of the cover (206) movement of the impactor arm resets the pawl (280) lifting it out of engagement with the ratchet (282) and compressing spring (284) (Figure 29).

35d Figures 30 and 31 represent alternative forms of cassettes containing an elongate carrier bearing powdered medicament in accordance with the invention. Each cassette (210) comprising supply spool (212) , an idler roll (214) , a control roller (216) and a take-up spool (218). The elongate carrier passes from the r,upply spool around the idler and control rollers to the take-up spool.
The cassettes of Figures 30 and 31 differ from that. shown in Figures 13 and 14 in that they possess an 7_0 integral drive belt (282; . Z.'he purpose of the belt is to keep the rotational. movement of the supply and take-up spools in precisely the correct rel<~tionship to each other and to the control roller: regardless of the proportion of elongate carrier than has been parsed from on spool to another. This objective i~~ achieved :by the drive belt (282) being in frictional contact with the control roller (216) (beneath the elongate c:arrier), and with the outside surface of the elongate ca:rri.er on each of the spools . In order to achieve the necessary arc of contact between the 20 drive belt (282) anc~ the elongate carrier on the spools, the cassette additionally comprises rollers (284). The elongate carrier is advanced simply by driving the control roller (216) which causes the correct rotational movement of each spool. As each :pool is driven directly by the control roller (216), additional mechanisms to arrest the carrier spool and to wine. the elongate carrier on to the take-up spool are no longer required.
Figures 32 to 3~~ illustrate an inhalation device in accordance with the invention suitable for use with the 3c) cassettes of Figures 30 and 31. The cassette of Figure 30 is shown in the device of Fi.gu.res 34 and 35.

35e The cocking, triggering and impaction mechanism of the inhalation df-wice is shown in Figures 32 and 33 and these mechanisms have substantially identical components and modes of actior_ t;o those shown in Figures 13 to 29.
Like parts are indicated :by like reference numerals.
Figure 34 shows t;he cassette (210) mounted in the device with the cover (206) closed and Figure 35 shows the device in use with the impaction head (268) striking the exposed area of the r=_longat.e carrier.

Claims (29)

WHAT IS CLAIMED IS:
1. A dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier directly bearing a powdered medicament without the use of adhesive or microcapsules, the device being constructed and arranged such that areas of predetermined size of the elongate carrier are sequentially exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that particles of the powdered medicament of a size less than 10 microns from said exposed area of the elongate carrier are entrained within the air flow.
2. A device as claimed in claim 1 comprising means to advance the elongate carrier to expose an area of said carrier within the chamber, said means being operable prior to or during patient inhalation through the patient port.
3. A device as claimed in claim 1 or 2, comprising means for releasing medicament of respirable size from the exposed area of carrier.
4. A device as claimed in claim 3, in which the means for releasing medicament comprises electrical, piezo-electrical, electromagnetic or mechanical means for vibrating the exposed area of the carrier.
37 . A device as claimed in claim 4 , in which said means produces vibrations in the frequency range of from 5 to 50000Hz.
6. A device as claimed in claim 3, in which the means for releasing medicament comprises means for impacting or striking the exposed area of the carrier either singularly or by a plurality of such strikings or impactions.
7. A device as claimed in any one of claims 3 to 6, comprising means to hold the elongate carrier taut during vibration or impaction.
8. A device as claimed in claim 3, in which the means for releasing medicament comprises means for brushing or scraping the exposed area of the carrier by rotary or reciprocal motion.
9. A device as claimed in claim 3, in which the means for releasing medicament comprises means for dragging the carrier across a surface having irregularities.
10. A device as claimed in claim 3, in which the means for releasing medicament comprises means having an edge or corner having a small radius of curvature arranged such that the exposed surface of the elongate carrier is given a sharp convex curvature.
11. A device as claimed in claim 3, in which the means for releasing medicament causes an unexposed area of carrier to advance rapidly into the chamber and come to an abrupt halt causing medicament release, or causes a length of the carrier to take the form of a slackened loop which is rapidly straightened causing medicament release.
12. A device as claimed in claim 3, in which the means for releasing medicament comprises a source of a compressed or liquefied gas.
13. A device as claimed in any one of claims 3 to 12, in which the means for releasing medicament is actuated by inhalation at the patient port.
14. A device as claimed in claim 13, comprising a moveable vane for triggering the means for releasing medicament, the vane being movable upon inhalation through the patient port.
15. A device as claimed in claim 14, in which the vane acts as a cane-way valve allowing passage of air from the chamber to the patient port but not from the patient port to the chamber.
16. A device as claimed in any one of claims 2 to 15, comprising biasing means for operation of the means to advance the carrier and/or means for releasing medicament.
17. A device as claimed in claim 16, additionally comprising a cover for the patient port which is pivotal between open and closed positions, said biasing means being primed by opening said cover.
18. A device as claimed in any one of claims 1 to 17, in which said elongate carrier comprises an elongate substrate releasably supporting particles of powdered medicament, at least a portion of the particles having a particle size in the range from 1 to 10 µm.
19. A device as claimed in claim 18, in which the substrate of the elongate carrier is in the form of a tape or web which is wound on a spool, wound in the form of a roll or folded into a concertina arrangement.
20. A device as claimed in claim 18, in which the elongate carrier additionally comprises a backing layer comprising a metal foil, a polymeric material, a metallised polymeric material or paper.
21. A device as claimed in any one of claims 18 to 20, in which the elongate carrier comprises polyethylene, poly-propylene, polyester, polytetrafluoroethylene, a copolymer thereof or cellulose.
22. A device as claimed in any one of claims 18 to 21, in which a surface of the substrate of the elongate carrier comprises:
(i) one or more grooves of width 10 to 500 µm at the carrier surface and depth 10 to 500 µm, the grooves containing particles of powdered medicament, (ii) randomly orientated pores of diameter 0.1 to 100 µm, at least a portion of the pores being on the exterior surface and containing particles of powdered medicament, (iii) apertures of diameter 1 to 100 µm in at least one surface produced by laser drilling, the apertures containing particles of powdered medicament, or, (iv) an embossed surface.
23. A device as claimed in any one of claims 18 to 22, in which the substrate of the elongate carrier comprises woven or non-woven fibers having a diameter of from 0.1 to 100 µm.
24. A device as claimed in any one of claims 18 to 23, in which the medicament is selected from Salbutamol, Terbu-taline, Rimiterol, Fenoterol, Pirbuterol, Reproterol, Adrenaline, Isoprenaline, Ociprenaline, Ipratropium, Beclo-methasone, Betamethasone, Budesonide, Disodium Cromo-glycate, Nedocromil Sodium, Ergotamine, Salmeterol, Fluticasone, Formoterol, Insulin, Atropine, Prednisolone, Benzphetamine, Chlorphentermine, Amitriptyline, Imipramine, Clonidine, Actinomycin C, Bromocriptine, Buprenorphine, Propranolol, Lacicortone, Hydrocortisone, Fluocinolone, Triamcinclone, Dinoprost, Xylometazoline, Diazepam, Loraze-pam, Folic acid, Nicotinamide, Clenbuterol, Bitolterol, Ethinyloestradiol, Levonorgestrel and pharmaceutically acceptable salts thereof.
25. A device as claimed in any one of claims 18 to 24, in which the elongate carrier is in the form of a tape or web having a width of from 0.5 to 3 cm.
26. A device as claimed in any one of claims 18 to 25, wherein said device is housed in a cassette.
27. A device as claimed in claim 26, wherein the cassette comprises a pair of spools, the elongate carrier being wound on one spool and extending to the second spool, whereby advancement of the elongate carrier causes the elongate carrier to be unwound from the first spool and wound on the second spool.
28. A device as claimed in claim 27, wherein the cassette additionally comprises a drive belt in contact with the elongate carrier wound on the spools such that movement of the drive belt causes advancement of the elongate carrier.
29. A dry powder inhalation device comprising a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and a plurality of carrier sheets each directly releasably bearing a powdered medicament without the use of adhesive or microcapsules, the device being constructed and arranged such that each carrier sheet is sequentially exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to patient port through the chamber such that particles of the powdered medicament of a size less than 10 microns from said exposed carrier are entrained within the air flow.
CA002050298A 1989-04-28 1990-04-30 Dry powder inhalation device Expired - Fee Related CA2050298C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002354096A CA2354096A1 (en) 1989-04-28 1990-04-30 Dry powder inhalation device

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898909891A GB8909891D0 (en) 1989-04-28 1989-04-28 Device
GB89.09891 1989-04-28
PCT/US1990/002412 WO1990013328A1 (en) 1989-04-28 1990-04-30 Dry powder inhalation device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002354096A Division CA2354096A1 (en) 1989-04-28 1990-04-30 Dry powder inhalation device

Publications (2)

Publication Number Publication Date
CA2050298A1 CA2050298A1 (en) 1990-10-29
CA2050298C true CA2050298C (en) 2001-09-04

Family

ID=10655980

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002354096A Abandoned CA2354096A1 (en) 1989-04-28 1990-04-30 Dry powder inhalation device
CA002050298A Expired - Fee Related CA2050298C (en) 1989-04-28 1990-04-30 Dry powder inhalation device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002354096A Abandoned CA2354096A1 (en) 1989-04-28 1990-04-30 Dry powder inhalation device

Country Status (13)

Country Link
US (2) US5619984A (en)
EP (1) EP0472598B1 (en)
JP (1) JP3130925B2 (en)
KR (2) KR920700715A (en)
AU (1) AU644790B2 (en)
CA (2) CA2354096A1 (en)
DE (1) DE69027679T2 (en)
DK (1) DK0472598T3 (en)
ES (1) ES2091825T3 (en)
GB (2) GB8909891D0 (en)
HK (1) HK1006546A1 (en)
NZ (2) NZ248275A (en)
WO (1) WO1990013328A1 (en)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705614B1 (en) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
YU48707B (en) * 1990-03-02 1999-07-28 Glaxo Group Limited Inhalation device
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (en) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalation device
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
RU2068274C1 (en) * 1990-06-28 1996-10-27 Берингер Ингельгейм КГ Method and device for weighing medicinal preparate for inhalation and method of producing medicinal preparate
FR2667790A1 (en) * 1990-10-04 1992-04-17 Valois Cartridge for holding small doses of powder in the form of strips designed to be used in a powder inhaler, and its method of manufacture
FR2667509B1 (en) * 1990-10-04 1995-08-25 Valois POWDER INHALER, DEVICE FOR PACKAGING POWDER MICRODOSES IN THE FORM OF BANDS SUITABLE FOR USE IN A POWDER INHALER, AND METHOD FOR MANUFACTURING SUCH BANDS.
GB9024760D0 (en) * 1990-11-14 1991-01-02 Riker Laboratories Inc Inhalation device and medicament carrier
US5479948A (en) * 1993-08-10 1996-01-02 Philip Morris Incorporated Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor
FR2676929B1 (en) * 1991-05-30 1994-02-11 Aerosols Bouchage Ste Fse POWDER INHALER.
DE4142238A1 (en) * 1991-12-20 1993-06-24 Boehringer Ingelheim Kg POWDER INHALATOR WITH POWDER SUPPORT FROM REGULAR MICROSTRUCTURES
WO1993024166A2 (en) * 1992-06-04 1993-12-09 Glaxo Group Limited Inhalation device
SE9203570D0 (en) * 1992-11-27 1992-11-27 Astra Ab INHALES FOR MULTIPLE USE
SE9203743D0 (en) 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
US6250300B1 (en) 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
AU4066693A (en) * 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
FR2701653B1 (en) * 1993-02-18 1995-04-07 Valois Dosing device for the inhalation of dry powder.
CN1119833A (en) * 1993-03-03 1996-04-03 泰纳克斯公司 Dry powder inhalator medicament carrier
GB9314614D0 (en) * 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
US5388572A (en) * 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
GB9324391D0 (en) * 1993-11-26 1994-01-12 Minnesota Mining & Mfg Device for transmission of one-way torque
US5388573A (en) * 1993-12-02 1995-02-14 Tenax Corporation Dry powder inhalator medicament carrier
SE9400257D0 (en) * 1994-01-27 1994-01-27 Astra Ab spacer
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
EP0748213B1 (en) * 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
ATE251433T1 (en) * 1994-08-30 2003-10-15 Pharmacia Ab LIQUID CAN PACKAGING, EYE TREATMENT DEVICE AND USE THEREOF
GB9417399D0 (en) 1994-08-30 1994-10-19 Scherer Corp R P Ocular treatment device
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
EP0987041B1 (en) * 1994-10-21 2003-02-05 SmithKline Beecham Corporation Medicament carrier for dry powder inhalator (and process for forming the same)
US5642727A (en) * 1995-07-25 1997-07-01 David Sarnoff Research Center, Inc. Inhaler apparatus using a tribo-electric charging technique
US5988163A (en) * 1995-08-02 1999-11-23 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of delivery of medicament
US5692496A (en) * 1995-08-02 1997-12-02 Innovative Devices, Llc Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5823183A (en) * 1995-08-02 1998-10-20 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US6026809A (en) * 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
US5694920A (en) * 1996-01-25 1997-12-09 Abrams; Andrew L. Inhalation device
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US5858099A (en) 1996-04-09 1999-01-12 Sarnoff Corporation Electrostatic chucks and a particle deposition apparatus therefor
IL127449A0 (en) * 1996-06-10 1999-10-28 Sarnoff Corp Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5857456A (en) * 1996-06-10 1999-01-12 Sarnoff Corporation Inhaler apparatus with an electronic means for enhanced release of dry powders
GB2320489A (en) * 1996-12-20 1998-06-24 Norton Healthcare Ltd Inhaler dose counter
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
SE9700936D0 (en) * 1997-03-14 1997-03-14 Astra Ab Inhalation device
US6006747A (en) * 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
CA2212430A1 (en) * 1997-08-07 1999-02-07 George Volgyesi Inhalation device
US6237590B1 (en) 1997-09-18 2001-05-29 Delsys Pharmaceutical Corporation Dry powder delivery system apparatus
JP3557170B2 (en) * 1998-03-04 2004-08-25 デルシス ファーマシューティカル コーポレイション Pharmaceutical dry powder inhalation dispenser
US6149774A (en) 1998-06-10 2000-11-21 Delsys Pharmaceutical Corporation AC waveforms biasing for bead manipulating chucks
US6152130A (en) * 1998-06-12 2000-11-28 Microdose Technologies, Inc. Inhalation device with acoustic control
US6142146A (en) * 1998-06-12 2000-11-07 Microdose Technologies, Inc. Inhalation device
CN1623607B (en) * 1998-06-12 2011-03-30 微量技术公司 Air suction device for conveying powdery medicine from container
US6062213A (en) * 1998-06-16 2000-05-16 Fuisz Technologies Ltd. Single unit dose inhalation therapy device
JP2002535048A (en) 1999-01-22 2002-10-22 グラクソ グループ リミテッド Inhalation device
US6752148B1 (en) 1999-02-10 2004-06-22 Delsys Pharmaceutical Company Medicament dry powder inhaler dispensing device
US6223744B1 (en) 1999-03-16 2001-05-01 Multi-Vet Ltd. Wearable aerosol delivery apparatus
CA2369262A1 (en) 1999-04-13 2000-10-19 Sudha Nagarajan Pulmonary administration of dry powder formulations for treating infertility
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6730066B1 (en) 1999-08-03 2004-05-04 Pharmacia Ab Liquid delivery container
EP1220698B1 (en) * 1999-10-12 2004-07-21 SHL Medical AB Inhaler
ES2254164T3 (en) 1999-10-29 2006-06-16 Nektar Therapeutics DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSABILITY.
SE517806C2 (en) * 1999-11-11 2002-07-16 Microdrug Ag Dosing device for inhaler
GB9929486D0 (en) 1999-12-15 2000-02-09 Glaxo Group Ltd Inhalation delivery apparatus and method
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US7080642B2 (en) * 1999-12-22 2006-07-25 3M Innovative Properties Company Refillable device with counting means
GB9930602D0 (en) * 1999-12-24 2000-02-16 Glaxo Group Ltd Inhalation device
US7171965B2 (en) * 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6427688B1 (en) 2000-02-01 2002-08-06 Dura Pharmaceuticals, Icn. Dry powder inhaler
ATE366126T1 (en) * 2000-03-10 2007-07-15 Univ North Carolina DRY POWDER INHALERS, MULTIDOSE DRY POWDER MEDICINE PACKS, CONTROL SYSTEMS AND METHODS
US6971383B2 (en) 2001-01-24 2005-12-06 University Of North Carolina At Chapel Hill Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods
US6948494B1 (en) 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
GB0015034D0 (en) * 2000-06-21 2000-08-09 Glaxo Group Ltd Inhalation device
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
EP2292288B1 (en) * 2000-07-24 2017-10-25 Clinical Designs Limited Dispenser
GB0019715D0 (en) * 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
DE10040528A1 (en) * 2000-08-18 2002-02-28 Pari Gmbh Inhalation device and method for generating a particle mist for inhalation purposes
US6626173B2 (en) * 2001-01-08 2003-09-30 Iep Pharmaceutical Devices Inc. Dry powder inhaler
US6782887B2 (en) * 2001-01-12 2004-08-31 Becton, Dickinson And Company Medicament respiratory delivery device and cartridge
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
AU2002238801A1 (en) * 2001-03-20 2002-10-03 Trudell Medical International Nebulizer apparatus and method
EP1381417A4 (en) * 2001-04-26 2009-12-30 New England Pharm Inc Metered dose delivery device for liquid and powder agents
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
GB0125132D0 (en) * 2001-10-19 2001-12-12 Glaxo Group Ltd Medicament dispenser
GB0125134D0 (en) * 2001-10-19 2001-12-12 Glaxo Group Ltd Medicament dispenser
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
JP4681231B2 (en) * 2002-03-20 2011-05-11 マンカインド コーポレイション Inhaler
GB2401321B (en) * 2002-03-22 2005-12-07 Clinical Designs Ltd Can fixture
GB0209528D0 (en) * 2002-04-26 2002-06-05 Glaxo Group Ltd Medicament dispenser
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US7677411B2 (en) * 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US6904908B2 (en) 2002-05-21 2005-06-14 Trudell Medical International Visual indicator for an aerosol medication delivery apparatus and system
EP1535349B1 (en) * 2002-06-27 2014-06-25 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluating non-pharmaceutical dry powders
GB0216831D0 (en) * 2002-07-19 2002-08-28 Glaxo Group Ltd Medicament dispenser
GB0221493D0 (en) * 2002-09-17 2002-10-23 Glaxo Group Ltd Method for loading a medicament dispenser with a medicament carrier
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0303870D0 (en) * 2003-02-20 2003-03-26 Norton Healthcare Ltd Pre-metered dose magazine for breath-actuated dry powder inhaler
GB0304000D0 (en) * 2003-02-21 2003-03-26 Clinical Designs Ltd Dispenser
US7360537B2 (en) * 2003-04-16 2008-04-22 Trudell Medical International Antistatic medication delivery apparatus
ES2370395T3 (en) 2003-05-21 2011-12-15 Alexza Pharmaceuticals, Inc. USE OF A SOLID FUEL LAYER, MANUFACTURING PROCEDURE AND CORRESPONDING HEATING UNIT.
GB0317374D0 (en) * 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
JP2007505136A (en) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド Aerosol formulation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation
GB2407042B (en) * 2003-10-17 2007-10-24 Vectura Ltd Inhaler
US7451761B2 (en) * 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US7377277B2 (en) * 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
MXPA06005604A (en) * 2003-11-18 2007-01-30 Yansong Shan Healthy pleasurable inhalation device.
GB0327112D0 (en) * 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0328859D0 (en) * 2003-12-12 2004-01-14 Clinical Designs Ltd Dispenser and counter
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
MXPA06009515A (en) * 2004-02-24 2007-03-26 Microdose Technologies Inc Synthetic jet based medicament delivery method and apparatus.
US7861712B2 (en) * 2004-04-23 2011-01-04 Manta Product Development Sealed capsule including an integrated puncturing mechanism
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
PL1765288T3 (en) 2004-06-18 2013-04-30 Novartis Ag Tobramycin formualtions for treatment of endobronchial infections
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
BRPI0514263B8 (en) 2004-08-20 2021-05-25 Mannkind Corp method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
CA2586886C (en) * 2004-11-10 2013-09-10 Cipla Limited Inhaler device
WO2006062448A1 (en) * 2004-12-10 2006-06-15 Ernst Hörlins Ingenjörsbyrå Ab Dose inhaler with a dose counter
GB0507711D0 (en) 2005-04-15 2005-05-25 Vectura Group Plc Improved blister piercing
US20090107495A1 (en) * 2005-07-21 2009-04-30 National Institute For Materials Science Device for inhalation of medicine
GB0515584D0 (en) * 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
WO2007089477A2 (en) 2006-01-31 2007-08-09 Oriel Therapeutics, Inc. Dry powder inhalers having spiral travel paths, unit dose microcartridges with dry powder, related devices and methods
MX2008009325A (en) * 2006-02-20 2008-12-18 Boehringer Ingelheim Int Inhaler.
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AU2007224178B2 (en) * 2006-03-03 2013-03-07 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
US8127763B2 (en) * 2006-03-03 2012-03-06 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
JP5241714B2 (en) 2006-07-07 2013-07-17 プロテウス デジタル ヘルス, インコーポレイテッド Smart parenteral delivery system
FR2904229B1 (en) * 2006-07-25 2008-10-10 Valois Sas DEVICE FOR DISPENSING FLUID PRODUCT.
MX2009001944A (en) 2006-08-21 2009-04-16 Trudell Medical Int Respiratory muscle endurance training device and method for the use thereof.
DE102006044756A1 (en) * 2006-09-20 2008-04-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg inhaler
DE102006044755A1 (en) * 2006-09-20 2008-04-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg inhaler
WO2008042951A2 (en) * 2006-10-03 2008-04-10 Manta Product Development Inhalation devices and related methods
GB0622827D0 (en) * 2006-11-15 2006-12-27 Glaxo Group Ltd Sheet driver for use in a drug dispenser
CN104188907A (en) * 2007-02-11 2014-12-10 Map药物公司 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20100126507A1 (en) * 2007-03-21 2010-05-27 Cipla Limited Multi-dose inhaler device
US20090151722A1 (en) * 2007-07-06 2009-06-18 Vectura Delivery Devices Limited Inhaler
EP2011538B1 (en) * 2007-07-06 2016-02-17 Vectura Delivery Devices Limited Inhaler
EP2011537A1 (en) * 2007-07-06 2009-01-07 Vectura Delivery Devices Limited Inhaler
EP2211974A4 (en) 2007-10-25 2013-02-27 Proteus Digital Health Inc Fluid transfer port information system
US8419638B2 (en) 2007-11-19 2013-04-16 Proteus Digital Health, Inc. Body-associated fluid transport structure evaluation devices
GB0800457D0 (en) 2008-01-11 2008-02-20 Innovata Biomed Ltd Improvements in or relating to inhalers
GB0800459D0 (en) * 2008-01-11 2008-02-20 Innovata Biomed Ltd Improvements in or relating to inhalers
EP2082772A1 (en) * 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
WO2009105515A2 (en) 2008-02-21 2009-08-27 Trudell Medical International Respiratory muscle endurance training device and method for the use thereof
IL191190A0 (en) * 2008-05-01 2009-08-03 Dan Adler Dry powder inhaler
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2982550C (en) * 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (en) 2008-06-20 2013-12-11 曼金德公司 An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
BRPI1009072B1 (en) 2009-05-18 2021-06-22 Adamis Pharmaceuticals Corporation DEVICE FOR DRY POWDER INHALATION AND DEVICE FOR DRY POWDER STORAGE
US9125999B2 (en) 2009-05-18 2015-09-08 Adamis Pharmaceuticals Corporation Dry powder inhaler dose counters
NZ596564A (en) * 2009-05-21 2012-11-30 Microdose Therapeutx Inx Rotary cassette system for dry powder inhaler with blister packs, a vibrating element and a piercing element
US8985101B2 (en) 2009-05-21 2015-03-24 Microdose Therapeutx, Inc. Method and device for clamping a blister within a dry powder inhaler
ES2943333T3 (en) 2009-06-12 2023-06-12 Mannkind Corp Diketopiperazine microparticles with defined surface areas
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US9345848B2 (en) * 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2498848A2 (en) 2009-11-12 2012-09-19 Stc.Unm Dry powder inhaler with flutter dispersion member
CN104338219B (en) 2010-01-05 2017-10-24 微剂量治疗技术公司 inhalation device and method
AU2011210648B2 (en) 2010-02-01 2014-10-16 Otsuka Pharmaceutical Co., Ltd. Data gathering system
US8332020B2 (en) 2010-02-01 2012-12-11 Proteus Digital Health, Inc. Two-wrist data gathering system
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
CN103826988B (en) 2011-04-01 2016-03-09 曼金德公司 For the blister package of pharmaceutical kit
US8486002B2 (en) * 2011-04-19 2013-07-16 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and release-activatable tape
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013059631A1 (en) 2011-10-21 2013-04-25 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
JP6018640B2 (en) 2011-10-24 2016-11-02 マンカインド コーポレイション Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition
JP6284884B2 (en) 2011-11-25 2018-02-28 ビルギチ,マフムト Inhaler
EP2617448A1 (en) * 2012-01-20 2013-07-24 Almirall S.A. Inhalation device for powdered drugs
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10370183B2 (en) 2012-07-19 2019-08-06 Adamis Pharmaceuticals Corporation Powder feeding apparatus
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
GB201301192D0 (en) 2013-01-23 2013-03-06 Vectura Delivery Devices Ltd A blister piercing element for a dry powder inhaler
KR102391750B1 (en) 2013-03-15 2022-04-28 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
CN105451716A (en) 2013-07-18 2016-03-30 曼金德公司 Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
HUE054172T2 (en) 2013-08-07 2021-08-30 Bristol Myers Squibb Co Injection aid for use with an injection device and method of use
PT3052169T (en) 2013-10-01 2018-10-25 Novartis Ag Blister track inhaler device having a separate end path
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
MX2016012712A (en) 2014-04-04 2017-03-31 Lam Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions.
ES2825973T5 (en) 2014-08-28 2024-04-09 Norton Waterford Ltd Compliance monitoring module for a breath-actuated inhaler
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2015330905B2 (en) * 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
CN107427650A (en) 2015-01-14 2017-12-01 瑞必治公司 Powder process for dispersing and device
US10179215B2 (en) 2015-03-19 2019-01-15 Altria Client Services Llc Vaporizer for vaporizing a constituent of a plant material
US10765821B2 (en) 2015-03-19 2020-09-08 Altria Client Services Llc Vaporizer for vaporizing a constituent of a plant material
TWI597079B (en) * 2015-04-10 2017-09-01 微劑量醫療公司 Blister strip advance mechanism
US10986819B2 (en) * 2015-06-14 2021-04-27 Tobe Influence Innovation Ltd. Apparatus for disinfestation of beehives and method for controlling same
MX2018014121A (en) 2016-05-19 2019-04-29 Trudell Medical Int Smart valved holding chamber.
EP3984579A1 (en) 2016-07-08 2022-04-20 Trudell Medical International Smart oscillating positive expiratory pressure device
US10786638B2 (en) 2016-07-08 2020-09-29 Trudell Medical International Nebulizer apparatus and method
WO2018071425A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2018104805A1 (en) 2016-12-09 2018-06-14 Trudell Medical International Smart nebulizer
JP7312754B2 (en) 2018-01-04 2023-07-21 トゥルーデル メディカル インターナショナル Smart vibrating positive expiratory pressure device
US20210085897A1 (en) * 2018-04-06 2021-03-25 Lupin Inc. Medicament dispenser
US11458262B2 (en) 2019-06-25 2022-10-04 Altria Client Services Llc Capsules, heat-not-burn (HNB) aerosol-generating devices, and methods of generating an aerosol
USD916361S1 (en) 2019-06-25 2021-04-13 Altria Client Services Llc Aerosol-generating capsule
WO2021038467A1 (en) 2019-08-27 2021-03-04 Trudell Medical International Smart oscillating positive expiratory pressure device
US11789476B2 (en) 2021-01-18 2023-10-17 Altria Client Services Llc Heat-not-burn (HNB) aerosol-generating devices including intra-draw heater control, and methods of controlling a heater
US11910826B2 (en) 2021-01-18 2024-02-27 Altria Client Services Llc Heat-not-burn (HNB) aerosol-generating devices and capsules

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE25422C (en) * J. HASSLER in Baden - Soden, Reg.-Bez. Wiesbaden Apparatus for atomizing powdery substances for inhalation purposes
GB1479283A (en) * 1973-07-23 1977-07-13 Bespak Industries Ltd Inhaler for powdered medicament
DE2346730C3 (en) * 1973-09-17 1980-10-16 Carl Heyer Gmbh, Inhalationstechnik, 5427 Bad Ems Device for aerosol treatment of people, animals, objects, substances and the like in a treatment room
US3971377A (en) * 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
US3948264A (en) * 1975-05-21 1976-04-06 Mead Johnson & Company Inhalation device
US4147166A (en) * 1977-05-02 1979-04-03 American Cyanamid Company Oral inhalator powder dispenser
DE2837040C2 (en) * 1978-08-24 1982-10-21 Siemens AG, 1000 Berlin und 8000 München Liquid transport system for an inhalation device
GB2061735B (en) * 1979-10-30 1983-11-30 Riker Laboratories Inc Breath actuated device for administration of powdered medicaments by inhalation
DE3023648A1 (en) * 1980-06-24 1982-01-21 Jaeger, Erich, 8700 Würzburg DEVICE FOR EXAMINING THE RESPIRATORY RESPIRATORY SENSITIVITY
SE438261B (en) * 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
JPS5876038A (en) * 1981-10-28 1983-05-09 高森 正之 Evaporation apparatus of insecticide or aromatic agent
EP0079478A1 (en) * 1981-11-03 1983-05-25 Miles Laboratories, Inc. Medicament inhalation device
FR2516387A1 (en) * 1981-11-16 1983-05-20 Fabre Sa Pierre Medical nasal inhaler for volatile constituents in microcapsules - which are in dose batches evenly spaced along flexible backing strip
GB2122903B (en) * 1982-06-22 1986-11-05 Masayuki Takamori Vaporizers for vaporisable substances and support media for substances usable therewith
SE432054B (en) * 1982-09-10 1984-03-19 Anders Tamsen PROGRAMMABLE INJECTION AND INFUSION DEVICE
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8328808D0 (en) * 1983-10-28 1983-11-30 Riker Laboratories Inc Inhalation responsive dispensers
AU572322B2 (en) * 1984-07-27 1988-05-05 N.J. Phillips Pty. Limited Tape dispenser
US4712460A (en) * 1985-11-18 1987-12-15 Biotrack, Inc. Integrated drug dosage form and metering system
JPS62204756A (en) * 1986-03-04 1987-09-09 大研医工株式会社 Drug volatilizing method and apparatus
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
EP0290683A3 (en) * 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
BR8802287A (en) * 1987-05-12 1988-12-13 Glaxo Inc INHALATION DEVICE
US4933873A (en) * 1988-05-12 1990-06-12 Healthtech Services Corp. Interactive patient assistance device
GB2218831A (en) * 1988-05-17 1989-11-22 Mark John Newland Personal medical apparatus
US4984158A (en) * 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
US5153827A (en) * 1989-01-30 1992-10-06 Omni-Flow, Inc. An infusion management and pumping system having an alarm handling system
EP0705614B1 (en) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US4899839A (en) * 1989-06-14 1990-02-13 Dessertine Albert L Compliance and patient status monitoring system and method
US5036462A (en) * 1989-09-29 1991-07-30 Healthtech Services Corp. Interactive patient assistance and medication delivery systems responsive to the physical environment of the patient
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9016789D0 (en) * 1990-07-31 1990-09-12 Lilly Industries Ltd Medicament administering devices
FR2667509B1 (en) * 1990-10-04 1995-08-25 Valois POWDER INHALER, DEVICE FOR PACKAGING POWDER MICRODOSES IN THE FORM OF BANDS SUITABLE FOR USE IN A POWDER INHALER, AND METHOD FOR MANUFACTURING SUCH BANDS.
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
CA2112674C (en) * 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
EP0526166A2 (en) * 1991-07-29 1993-02-03 Albert L. Dessertine Patient compliance monitoring method and system
US5363842A (en) * 1991-12-20 1994-11-15 Circadian, Inc. Intelligent inhaler providing feedback to both patient and medical professional

Also Published As

Publication number Publication date
CA2354096A1 (en) 1990-11-15
DE69027679D1 (en) 1996-08-08
GB8909891D0 (en) 1989-06-14
ES2091825T3 (en) 1996-11-16
JPH04504671A (en) 1992-08-20
NZ248275A (en) 1995-05-26
WO1990013328A1 (en) 1990-11-15
AU644790B2 (en) 1993-12-23
US5740793A (en) 1998-04-21
NZ233486A (en) 1995-05-26
DK0472598T3 (en) 1996-07-29
GB9000261D0 (en) 1990-03-07
AU5558890A (en) 1990-11-29
KR920700715A (en) 1992-08-10
US5619984A (en) 1997-04-15
JP3130925B2 (en) 2001-01-31
EP0472598B1 (en) 1996-07-03
HK1006546A1 (en) 1999-03-05
EP0472598A1 (en) 1992-03-04
KR0178798B1 (en) 1999-04-01
CA2050298A1 (en) 1990-10-29
DE69027679T2 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
CA2050298C (en) Dry powder inhalation device
EP0470154B1 (en) Dry powder inhalation device
CA2039655C (en) Sheet for containing micronized powdered medicament
EP1061982B1 (en) Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5645050A (en) Powder inhaler with powder carrier consisting of regular microstructures
US5408994A (en) Inhalation device
CA2086123C (en) Apparatus and process for metering powder
AU703618B2 (en) Medicament carrier for dry powder inhalator and process for forming the same
AU1472099A (en) Medicament carrier for dry powder inhalator and process for forming the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed